Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

A brief glimpse over the horizon for type 1 diabetes nanotherapeutics.

Garciafigueroa Y, Trucco M, Giannoukakis N.

Clin Immunol. 2015 Mar 25. pii: S1521-6616(15)00116-3. doi: 10.1016/j.clim.2015.03.016. [Epub ahead of print]

PMID:
25817545
2.

Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation.

Engman C, Wen Y, Meng WS, Bottino R, Trucco M, Giannoukakis N.

Clin Immunol. 2015 Mar 12. pii: S1521-6616(15)00094-7. doi: 10.1016/j.clim.2015.03.004. [Epub ahead of print]

PMID:
25773782
3.

Cellular therapies based on stem cells and their insulin-producing surrogates: a 2015 reality check.

Giannoukakis N, Trucco M.

Pediatr Diabetes. 2015 May;16(3):151-63. doi: 10.1111/pedi.12259. Epub 2015 Feb 5.

PMID:
25652322
4.

Antibody-functionalized peptidic membranes for neutralization of allogeneic skin antigen-presenting cells.

Wen Y, Liu W, Bagia C, Zhang S, Bai M, Janjic JM, Giannoukakis N, Gawalt ES, Meng WS.

Acta Biomater. 2014 Nov;10(11):4759-67. doi: 10.1016/j.actbio.2014.08.003. Epub 2014 Aug 10.

PMID:
25117952
5.

Evaluation of ranirestat for the treatment of diabetic neuropathy.

Giannoukakis N.

Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):1051-9. doi: 10.1517/17425255.2014.916277. Epub 2014 Apr 30. Review.

PMID:
24785785
6.

Coassembly of amphiphilic peptide EAK16-II with histidinylated analogues and implications for functionalization of β-sheet fibrils in vivo.

Wen Y, Roudebush SL, Buckholtz GA, Goehring TR, Giannoukakis N, Gawalt ES, Meng WS.

Biomaterials. 2014 Jun;35(19):5196-205. doi: 10.1016/j.biomaterials.2014.03.009. Epub 2014 Mar 28.

PMID:
24680662
7.

Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice.

Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N.

PLoS One. 2014 Jan 17;9(1):e83575. doi: 10.1371/journal.pone.0083575. eCollection 2014.

8.

It's time to bring dendritic cell therapy to type 1 diabetes.

Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG.

Diabetes. 2014 Jan;63(1):20-30. doi: 10.2337/db13-0886. Review. No abstract available.

9.
10.

Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes.

Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N.

Clin Exp Immunol. 2013 Nov;174(2):302-17. doi: 10.1111/cei.12177.

11.

Tolerogenic dendritic cells for Type 1 diabetes.

Giannoukakis N.

Immunotherapy. 2013 Jun;5(6):569-71. doi: 10.2217/imt.13.50.

PMID:
23725280
12.

Retaining antibodies in tumors with a self-assembling injectable system.

Wen Y, Kolonich HR, Kruszewski KM, Giannoukakis N, Gawalt ES, Meng WS.

Mol Pharm. 2013 Mar 4;10(3):1035-44. doi: 10.1021/mp300504z. Epub 2013 Feb 18.

PMID:
23419203
13.

Dendritic cell therapy for Type 1 diabetes suppression.

Giannoukakis N, Trucco M.

Immunotherapy. 2012 Oct;4(10):1063-74. doi: 10.2217/imt.12.76. Review.

PMID:
23148758
14.

A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus.

Giannoukakis N, Trucco M.

Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):279-87. doi: 10.1097/MED.0b013e328355461b. Review.

PMID:
22760513
15.

Sequence variation in promoter of Ica1 gene, which encodes protein implicated in type 1 diabetes, causes transcription factor autoimmune regulator (AIRE) to increase its binding and down-regulate expression.

Bonner SM, Pietropaolo SL, Fan Y, Chang Y, Sethupathy P, Morran MP, Beems M, Giannoukakis N, Trucco G, Palumbo MO, Solimena M, Pugliese A, Polychronakos C, Trucco M, Pietropaolo M.

J Biol Chem. 2012 May 18;287(21):17882-93. doi: 10.1074/jbc.M111.319020. Epub 2012 Mar 24.

16.

In vivo delivery of nucleic acid-formulated microparticles as a potential tolerogenic vaccine for type 1 diabetes.

Di Caro V, Giannoukakis N, Trucco M.

Rev Diabet Stud. 2012 Winter;9(4):348-56. doi: 10.1900/RDS.2012.9.348. Epub 2012 Dec 28. Review.

17.

FoxO6 integrates insulin signaling with gluconeogenesis in the liver.

Kim DH, Perdomo G, Zhang T, Slusher S, Lee S, Phillips BE, Fan Y, Giannoukakis N, Gramignoli R, Strom S, Ringquist S, Dong HH.

Diabetes. 2011 Nov;60(11):2763-74. doi: 10.2337/db11-0548. Epub 2011 Sep 22.

18.

Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?

Phillips B, Trucco M, Giannoukakis N.

Clin Dev Immunol. 2011;2011:432016. doi: 10.1155/2011/432016. Epub 2011 Jul 18. Review.

19.

Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.

Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M.

Diabetes Care. 2011 Sep;34(9):2026-32. doi: 10.2337/dc11-0472. Epub 2011 Jun 16.

20.

Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.

Di Caro V, D'Anneo A, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N.

Immunol Res. 2011 Aug;50(2-3):130-52. doi: 10.1007/s12026-011-8206-1.

PMID:
21476100
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk